What is BioMarin Pharmaceuticals's GALAFOLD — total revenues?

BioMarin Pharmaceuticals (BMRN) reported GALAFOLD — total revenues of $105.75M in Q2 2026.

What does GALAFOLD — total revenues mean?

This metric represents the total net sales generated from the commercialization of a specific therapeutic product within the company's rare disease portfolio. It reflects the market adoption, pricing strategy, and patient demand for this particular treatment. Tracking these revenues is essential for evaluating the product's lifecycle performance and its contribution to the company's overall top-line growth.

BioMarin Pharmaceuticals (BMRN) GALAFOLD — Total revenues

Screener

Other product segments

VOXZOGO

$252.53M+14.1%

VIMIZIM

$194.37M-9.8%

NAGLAZYME

$135.26M+5.0%

PALYNZIQ

$135.17M+27.6%

BRINEURA

$51.37M+5.5%

ALDURAZYME

$43.54M-22.9%

POMBILITI + OPFOLDA

$30.26M—

KUVAN

$24.44M-9.6%

ROCTAVIAN

$11.71M+27.3%

Royalty and other revenues

$5.32M-57.2%

Similar metrics at other companies

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

ALN

ALNYRoyalty revenue — Total revenues

$71.67M+79.3%

HContra revenue — Total revenues

-$17M-13.3%

FTAIMaintenance revenue — Total revenues

$30.6M-38.3%

FTAIOther revenue — Total revenues

$6.21M+19,923%

Other financials

Income statement

See full

Revenue$989.7M+19.9%

Gross profit$786.9M+16.5%

Operating income$110.9M-59.9%

Net income$44.8M-81.4%

EPS (diluted)$0.23-81.3%

Balance sheet

See full

Cash & equivalents$874.0M-28.0%

Total debt$4.2B+598%

Total equity$6.3B+4.9%

Total assets$11.7B+57.2%

Cash flow

See full

Operating cash flow$168.1M-9.3%

CapEx$28.8M+68.5%

Free cash flow$139.3M-17.2%

Valuation

See full

Market cap$11.58B-0.6%

Enterprise value$14.89B+34.9%

P/E32.2×-34.7×

P/S3.4×-0.4×

Profitability

See full

Gross margin76.1%-3.4pp

Operating margin19.9%+7.2pp

Net margin16.8%+5.1pp

FCF margin21.7%-1.0pp

Returns & leverage

See full

Return on equity9.1%+2.8pp

Debt / equity0.7×+0.6×

Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 4:14 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001048477-26-000016

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
VIMIZIM	194,371	215,424	404,575	403,770
NAGLAZYME	135,255	128,867	265,329	243,157
PALYNZIQ	135,167	105,938	224,725	199,207
GALAFOLD(1)	105,748	—	105,748	—
BRINEURA	51,370	48,692	98,474	89,054
ALDURAZYME	43,539	56,437	80,281	105,414
POMBILITI + OPFOLDA(1)	30,258	—	30,258	—
KUVAN	24,444	27,034	48,324	52,170

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's GALAFOLD — total revenues?: BioMarin Pharmaceuticals (BMRN) reported GALAFOLD — total revenues of $105.75M in Q2 2026.
What does GALAFOLD — total revenues mean?: This metric represents the total net sales generated from the commercialization of a specific therapeutic product within the company's rare disease portfolio. It reflects the market adoption, pricing strategy, and patient demand for this particular treatment. Tracking these revenues is essential for evaluating the product's lifecycle performance and its contribution to the company's overall top-line growth.